HURA Stock Summary and Trading Ideas (Tuhura Biosciences | NASDAQ:HURA)

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Tuhura Biosciences trades on the NASDAQ stock market under the symbol HURA.

As of July 23, 2026, HURA stock price declined to $2.15 with 166,845 million shares trading.

HURA has a beta of 2.70, meaning it tends to be more sensitive to market movements. HURA has a correlation of 0.05 to the broad based SPY ETF.

HURA has a market cap of $136.92 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that HURA belongs to (by Net Assets): VTI, VXF, IWC.

HURA has underperformed the market in the last year with a price return of -21.5% while the SPY ETF gained +18.6%. HURA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.8% and -5.7%, respectively, while the SPY returned +4.1% and -1.0%, respectively.

HURA support price is $2.11 and resistance is $2.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HURA shares will trade within this expected range on the day.